Redcare Pharmacy Shares Plunge as New CFO Takes Helm

The appointment of a new Chief Financial Officer typically signals fresh momentum and renewed confidence. For Redcare Pharmacy, however, the market's reaction has been a stark departure from this norm. Investors are exiting in droves following the official start of Hendrik Krampe as CFO this past Monday, his succession of Jasper Eenhorst met with further share price declines instead of applause. The sustained downward spiral forces a critical evaluation: has investor trust been irreparably broken, or does the steep drop present a potential entry point?

A glaring divergence defines the current situation: the stark contrast between expert price targets and actual market sentiment. Several analysts continue to advocate for ambitious targets exceeding €150, pinning their long-term faith on the company's CardLink technology. Yet reality is delivering a harsh lesson. The share price has now fallen below even the more conservative estimates, demonstrating how bullish forecasts are being overtaken by events. In today's risk-averse climate, the market is completely disregarding these lofty projections, subjecting previous "buy" recommendations to a brutal reality check and creating a perilous environment for shareholders.

Should investors sell immediately? Or is it worth buying Redcare Pharmacy?

Performance Pressure Mounts Immediately

There is no customary grace period for the new finance chief. The market has almost pointedly ignored this management change, allowing no welcome rally and instead continuing the grueling downtrend that has characterized the stock's performance throughout 2025. The message from investors is unambiguous: merely changing personnel is insufficient; tangible financial results are now demanded. Skepticism primarily centers on the difficult balance between aggressive growth in the e-prescription segment and the urgently needed path to profitability. Krampe faces the Herculean task of steering the company's financial course toward proving that revenue growth can be transformed into sustainable cash flow.

A Descent with No Clear Bottom in Sight

The scale of the challenge is crystallized in the share price trajectory. Since the start of the year, the equity has been in a free fall, losing more than 50% of its value. It currently trades at just €63.40, desperately searching for a floor after breaking through several key psychological support levels. With no verifiable progress visible on the balance sheet, pressure is likely to remain intense. For market participants, this signals a need for extreme caution, as the current climate shows no mercy for investment theses built on hope alone.